ASPR 23-103-S LSJ Leukine Injectables_Approved-Redaction_Redacted.pdf

This Limited Sources Justification document from the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response approves a sole source contract award to provide Leukine injectables. The solicitation seeks to acquire Leukine, a drug used to treat neutropenia, from a single manufacturer for the Strategic National Stockpile through December 2023. The justification cites Leukine's unique manufacturing process and the risks associated with switching to an alternative product as rationale for the noncompetitive award. The contractor will supply Leukine at a fixed unit price of $6,000 per vial through the end of the contract period.